Display options
Cite
Esmaeili-Mahani S, Falahi F, Yaghoobi MM. Proapoptotic and Antiproliferative Effects of Thymus caramanicus on Human Breast Cancer Cell Line (MCF-7) and Its Interaction with Anticancer Drug Vincristine. Evid Based Complement Alternat Med. 2014;2014:893247doi: 10.1155/2014/893247.
Esmaeili-Mahani, S., Falahi, F., & Yaghoobi, M. M. (2014). Proapoptotic and Antiproliferative Effects of Thymus caramanicus on Human Breast Cancer Cell Line (MCF-7) and Its Interaction with Anticancer Drug Vincristine. Evidence-based complementary and alternative medicine : eCAM, 2014893247. https://doi.org/10.1155/2014/893247
Esmaeili-Mahani, Saeed, et al. "Proapoptotic and Antiproliferative Effects of Thymus caramanicus on Human Breast Cancer Cell Line (MCF-7) and Its Interaction with Anticancer Drug Vincristine." Evidence-based complementary and alternative medicine : eCAM vol. 2014 (2014): 893247. doi: https://doi.org/10.1155/2014/893247
Esmaeili-Mahani S, Falahi F, Yaghoobi MM. Proapoptotic and Antiproliferative Effects of Thymus caramanicus on Human Breast Cancer Cell Line (MCF-7) and Its Interaction with Anticancer Drug Vincristine. Evid Based Complement Alternat Med. 2014;2014:893247. doi: 10.1155/2014/893247. Epub 2014 Apr 09. PMID: 24812569; PMCID: PMC4000631.
Copy Download .nbib Format: NLM
Share it on

Evid Based Complement Alternat Med. 2014;2014:893247. doi: 10.1155/2014/893247. Epub 2014 Apr 09.

Proapoptotic and Antiproliferative Effects of Thymus caramanicus on Human Breast Cancer Cell Line (MCF-7) and Its Interaction with Anticancer Drug Vincristine.

Evidence-based complementary and alternative medicine : eCAM

Saeed Esmaeili-Mahani, Farzaneh Falahi, Mohammad Mehdi Yaghoobi

Affiliations

  1. Laboratory of Molecular Neuroscience, Kerman Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran ; Department of Biology, Faculty of Sciences, Shahid Bahonar University of Kerman, P.O. Box 76135-133, Kerman, Iran.
  2. Laboratory of Molecular Neuroscience, Kerman Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran ; Research Department of Biotechnology, Institute of Science and High Technology and Environmental Sciences, Graduate University of Advanced Technology, Kerman, Iran.
  3. Research Department of Biotechnology, Institute of Science and High Technology and Environmental Sciences, Graduate University of Advanced Technology, Kerman, Iran.

PMID: 24812569 PMCID: PMC4000631 DOI: 10.1155/2014/893247

Abstract

Thymus caramanicus Jalas is one of the species of thymus that grows in the wild in different regions of Iran. Traditionally, leaves of this plant are used in the treatment of diabetes, arthritis, and cancerous situation. Therefore, the present study was designed to investigate the selective cytotoxic and antiproliferative properties of Thymus caramanicus extract (TCE). MCF-7 human breast cancer cells were used in this study. Cytotoxicity of the extract was determined using MTT and neutral red assays. Biochemical markers of apoptosis (caspase 3, Bax, and Bcl-2) and cell proliferation (cyclin D1) were evaluated by immunoblotting. Vincristine was used as anticancer control drug in extract combination therapy. The data showed that incubation of cells with TCE (200 and 250  μ g/mL) significantly increased cell damage, activated caspase 3 and Bax/Bcl2 ratio. In addition, cyclin D1 was significantly decreased in TCE-treated cells. Furthermore, concomitant treatment of cells with extract and anticancer drug produced a significant cytotoxic effect as compared to extract or drugs alone. In conclusion, thymus extract has a potential proapoptotic/antiproliferative property against human breast cancer cells and its combination with chemotherapeutic agent vincristine may induce cell death effectively and be a potent modality to treat this type of cancer.

References

  1. Cytotechnology. 2003 Nov;43(1-3):149-54 - PubMed
  2. Arch Pharm (Weinheim). 2010 Sep;343(9):489-99 - PubMed
  3. Breast Cancer Res. 2013 Jan 21;15(1):R5 - PubMed
  4. Evid Based Complement Alternat Med. 2012;2012:728065 - PubMed
  5. J Agric Food Chem. 2012 Mar 14;60(10):2746-52 - PubMed
  6. Int J Oncol. 2011 Dec;39(6):1501-9 - PubMed
  7. Surg Clin North Am. 2013 Apr;93(2):473-91 - PubMed
  8. J Ethnopharmacol. 2012 Sep 28;143(2):406-11 - PubMed
  9. Cancer Prev Res (Phila). 2012 Feb;5(2):179-88 - PubMed
  10. Biomed Tech (Berl). 2007 Feb;52(1):164-8 - PubMed
  11. Biochem Biophys Res Commun. 2000 Apr 13;270(2):415-20 - PubMed
  12. Mol Biol Rep. 2012 May;39(5):5465-71 - PubMed
  13. Cell Cycle. 2007 May 2;6(9):1102-14 - PubMed
  14. J Agric Food Chem. 2002 Mar 27;50(7):1845-51 - PubMed
  15. Genes Dev. 1993 May;7(5):812-21 - PubMed
  16. Antioxid Redox Signal. 2013 Aug 20;19(6):546-58 - PubMed
  17. CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29 - PubMed
  18. Apoptosis. 2007 Sep;12(9):1543-68 - PubMed
  19. Food Chem. 2008 Oct 15;110(4):927-31 - PubMed
  20. Br J Cancer. 1995 Jan;71(1):64-8 - PubMed
  21. Prostate. 1999 Jan 1;38(1):40-5 - PubMed
  22. Phytomedicine. 2010 Jul;17(8-9):581-8 - PubMed
  23. J Pharm Biomed Anal. 2002 Jul 20;29(4):691-700 - PubMed
  24. Food Chem. 2013 Aug 15;139(1-4):138-43 - PubMed
  25. Int J Oncol. 2013 Feb;42(2):733-40 - PubMed
  26. Anticancer Res. 2004 Sep-Oct;24(5A):2783-840 - PubMed
  27. Int J Oncol. 2006 Nov;29(5):1269-78 - PubMed
  28. Nat Rev Cancer. 2011 Mar;11(3):211-8 - PubMed
  29. Anticancer Res. 2006 Nov-Dec;26(6B):4559-68 - PubMed
  30. Exp Oncol. 2006 Jun;28(2):121-5 - PubMed

Publication Types